Keyphrases
In Vitro Study
100%
Triple-negative Breast Cancer
100%
PARP Inhibitor (PARPi)
100%
Auger Emitters
100%
I-125
50%
Breast Cancer Cell Lines
25%
Triple-negative Breast Cancer Cells
25%
Monotherapy
12%
Breast Cancer Patients
12%
Cytotoxicity
12%
Therapeutic Efficacy
12%
Therapeutic Effect
12%
DNA Damage
12%
Radiosynthesis
12%
DNA Double-strand Breaks
12%
Olaparib
12%
Clonogenic Survival
12%
Combined Treatment
12%
Chemotherapy
6%
Resistant Cell Lines
6%
Lack of Response
6%
Recurrence Rate
6%
Cancer Cell Lines
6%
Flow Cytometry
6%
Breast Cancer Subtypes
6%
Doxorubicin
6%
Nuclear Proteins
6%
Therapeutic Evaluation
6%
Low-dose Radiation
6%
Immunofluorescence Staining
6%
Aggressive Subtypes
6%
Growth Potential
6%
Metastatic Breast Cancer
6%
BRCA mutation
6%
Radionuclides
6%
γH2AX
6%
PARP-1 Inhibitor
6%
Life Cycle Analysis
6%
Therapeutic Efficiency
6%
Delivery Mechanisms
6%
Anchorage-independent Growth
6%
Theranostic Approach
6%
Apoptosis Assay
6%
Homologous Recombination Deficiency
6%
DNA Repair Deficiency
6%
Nuclear Delivery
6%
Soft Agar Assay
6%
Nuclear Positioning
6%
Blocking Assay
6%
Combined Therapy
6%
Radiotherapeutics
6%
INIS
cancer
100%
therapy
100%
breasts
100%
in vitro
100%
iodine 125
66%
dna
25%
patients
16%
specificity
16%
toxicity
16%
dna damages
16%
induction
16%
panels
16%
metastases
16%
strand breaks
16%
combined therapy
8%
efficiency
8%
delivery
8%
mutations
8%
radiations
8%
apoptosis
8%
inhibition
8%
chemotherapy
8%
evaluation
8%
proteins
8%
growth
8%
labelling
8%
blocking
8%
dna repair
8%
doxorubicin
8%
agar
8%
cell cycle
8%
radionuclides
8%
gene recombination
8%
theranostics
8%
Medicine and Dentistry
In Vitro
100%
Triple Negative Breast Cancer
100%
PARP Inhibitor
100%
Iodine 125
72%
Breast Cancer Cell Line
36%
Cell Line
27%
PARP1
27%
DNA Damage
18%
Combination Therapy
18%
Monotherapy
18%
Therapy Effect
18%
Cytotoxicity
18%
DNA Strand
18%
Olaparib
18%
Breast Cancer
9%
Recurrence Risk
9%
Immunofluorescence
9%
DNA Repair
9%
Metastatic Breast Cancer
9%
Doxorubicin
9%
Flow Cytometry
9%
Radioisotope
9%
BRCA Mutation
9%
Combined Therapy
9%
Agar
9%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase 1
9%
Nuclear Protein
9%
Homologous Recombination
9%
Resistant Cell Line
9%
Apoptosis Assay
9%
Cell-Cycle Analysis
9%
Anchorage Independent Growth
9%
Poly ADP Ribose Polymerase
9%
Chemotherapy
9%
Pharmacology, Toxicology and Pharmaceutical Science
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
100%
Triple Negative Breast Cancer
100%
Iodine-125
72%
Monotherapy
18%
Combination Therapy
18%
Therapeutic Effect
18%
Olaparib
18%
Cytotoxicity
18%
Doxorubicin
9%
Breast Cancer
9%
Chemotherapy
9%
Metastatic Breast Cancer
9%
Flow Cytometry
9%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase 1
9%
Recurrence Risk
9%
Radioisotope
9%
Nuclear Protein
9%
Agar
9%
Apoptosis Assay
9%